Halozyme Therapeutics Beats Q4 Views; Outlook Shy Of Consensus
March 02, 2015 at 18:59 PM EST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) posted better-than expected fourth quarter results on Monday, but offered a revenue forecast ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.